This is a preview of subscription content, log in via an institution to check access.
References
Movsowitz C, Marchlinski FE. Interactions between implantable cardioverter-defibrillators and Class III agents. Am J Cardiol 1998;82:41I-48I.
Brode SE, Schwartzman D, Callans DJ, Gottlieb CD, Marchlinski FE. ICD-antiarrhythmic drug and ICD-pacemaker interactions. J Cardiovasc Electrophysiol 1997:830-842.
Reiter MJ, Mann DE. Sensing and tachyarrhythmia detection problems in implantable cardioverter defibrillators. J Cardiovasc Electrophysiol 1996;7:542-558.
Newman D, Dorian P, Hardy J. Randomized controlled comparison of antitachycardia pacing algorithms for termination of ventricular tachycardia. J Am Coll Cardiol 1993;21:1413-1418.
Bardy GH, Yee R, Jung W. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. J Am Coll Cardiol 1996;26:400-410.
Jones DL, Klein GJ, Guiraudon GM, Yee R, Brown JE, Sharma AD. Effects of lidocaine and verapamil on defibrillation in humans. J Electrocardiol 1991;24:299-305.
Stevens SK, Haffajee CI, Naccarelli GV, Schwartz KM, Luceri RM, Packer DL, Kowey PR. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implanted cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators. J Am Coll Cardiol 1996;28:418-422.
Epstein AE, Ellenbogen KA, Kirk KA, et al. Clinical characteristics and outcome of patients with high defibrillation thresholds. Circulation 1992;86:1206-1216.
Jung W, Manz M, Pizzuli L, Pfeiffer D, Luderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992;70:1023-1027.
Kuhlkamp V, Mewis C, Suchalla R, Mermi J, Dornberger V, Seipel L. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. Int J Cardiol 1999;69:271-279.
Ujhelyi MR, Schur M, Frede T, Gabel M, Markel ML. Differential effects of lidocaine on defibrillation threshold with monophasic versus biphasic shock waveforms. Circulation 1995;92:1644-50.
Dorian P, Newman D, Sheahan R, Tang A, Green M, Mitchell J. D-sotalol decreases defibrillation energy requirements in humans. A novel indication for drug therapy. J Cardiovasc Electrophysiol 1996;7:952-961.
Manz M, Jung W, Luderitz B. Interactions between drugs and devices: Experimental and clinical studies. Am Heart J 1994;127:978-984.
Levine JH, Mellits D, Baumgardner RA, Veltri EP, Mower M, Grunwald L, Guarnieri T, Aarons D, Griffith LSC. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation 1991;84:558-566.
Kuhlkamp V, Mewis C, Mermi J, Bosch RF, Seipel L. Suppression of sustained ventricular tachyarrhythmias: A comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol 1999;26:46-52.
Dorian P, Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol 1993;72:72A-79A.
Dolak GL for the CASCADE Investigators. Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE Trial). Am J Cardiol 1994;73:237-241.
Greene M, Newman D, Geist M, Paquette M, Heng D, Dorian P. Is electrical storm in ICD patients the sign of a dying heart? Outcome of patients with clusters of tachyarrhythmias. Europace. (in press)
Dorian P, Cass D. An overview of the management of electrical storm. Can J Cardiol 1997;13(Suppl A):13A-17A.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pintér, A., Dorian, P. Interactions Between Implantable Devices and Antiarrhythmic Drugs. Card Electrophysiol Rev 4, 222–226 (2000). https://doi.org/10.1023/A:1026527027988
Issue Date:
DOI: https://doi.org/10.1023/A:1026527027988